Bulk Fill – Market Overview

August 13, 2021

이 페이지 공유

State of the Industry:

 

Over the last 20 years, there has been a rapid growth in the development of therapeutic molecules and biologics including recombinant proteins, monoclonal antibodies and, most recently, viral vectors. To improve access to these life-saving therapies, it has become vital for drug manufacturers to increase productivity and optimize the use of process equipment while improving product quality.

 

Whilst the focus of improvement measures has been directed towards bioreactors, tangential flow filtration (TFF) and chromatography equipment in order to improve commercial-scale manufacturing, one vital step in the manufacturing process has sadly been neglected. By not prioritizing bulk filling in their approach, manufacturers have unfortunately missed a key section in the total manufacturing workflow and have overlooked the impact of bulk filling on the process productivity and the potential contribution that improvements to this step can deliver. Significant improvement in the areas of suite turnover, process step yield and process risk could all be unlocked if the challenges associated with bulk filling can be solved.

 

Focusing on Herbie:

 

The objective of commercial-scale biologics manufacturing is to make a product as fast and as cost-effective as possible while maintaining product quality. Improving the speed and cost of manufacturing needs a holistic approach and, typically, involves analyzing the entire workflow. As complex as the biologics manufacturing process is, it can be broken down into a series of dependent steps and activities, one of which acts as a constraint upon the entire process. This is the Theory of Constraints conceived by Dr. Eliyahu Goldratt and popularized by his novel, “The Goal”, in the 1980s. The big idea of this theory is that improvement effort should be directed towards the top priority – namely the current constraint. The novel’s protagonist draws a parallel between a production process and that of a Boy Scout hiking troop supervised by only one adult. The objective is that the group needs to hike as quickly as possible to reach their campsite before dark while staying close together ensuring everyone’s safety. The speed of the entire troop is linked to that of one boy, Herbie, and the story goes on to describe the discovery and implementation process the troop follows to lighten Herbie’s backpack and distribute it over all members in order to reach their destination as fast as possible. In this example, the objective centered around speed, but it must be emphasized here that the objective(s) may be different dependent on the environment, business goals and problem definition.

 

A subtlety often missed when applying the theory is that the constraint may ‘shift’ to a different process step as the constraints are addressed in priority order. So, while focus in the areas of bioreactors and TFF equipment, for example, may have been sorely needed by industry, their advancement has exposed the limitations of current bulk filling practices and any more investment would have limited benefits to the overall facility throughput without addressing this. Before COVID-19, drug manufacturers were searching for ways to improve their step yield as well as their suite turnover rate – industry speak for more batches per year – a metric to drive increased asset utilization and improve cost efficiency. With only a limited number of facilities in the world, now, more than ever before, facility throughput has been highlighted as critical to manufacturing enough vaccine for the human population. 

 

Bulk Filling:

 

Bulk filling is the process of dividing a large volume of product into smaller containers. In a biotechnology context, it is the critical management of process fluid – drug substance, cell culture media or buffer - usually involving a low-bioburden or sterile filtration step (qualification dependent), is mainly associated with the accurate filling of multiple 2D biocontainer bags or bottles in the 500 mL to 20 L (nominal) range, and excludes the filling of syringes, vials or ampules. Although bulk filling is strongly linked to the (fluid) management of drug substance following final concentration/diafiltration, it is also an essential workflow step in buffer and media processing as well as cell banking activities.

 

For the past 10-15 years, polycarbonate bottles have been the container of choice in bulk filling operations. For all their benefits in robustness, bottles suffer from three unavoidable problems owing to their design; (1) they need to be opened, filled and closed under a laminar fume hood to maintain low-bioburden, (2) their design makes them incredibly bulky to ship and store, and (3) blast freezing product in bottles is time consuming and not scalable. A growing trend however is the transition from bottles to 2D biocontainer bags owing to the advances in film as well as significant benefits in higher packing/storage densities and plate freezers offering greater levels of scalability and tighter process control when freezing high value drug substance.

 

In the context of drug substance handling, the importance of bulk filling cannot be overstated; it is the last step in the (drug substance) manufacturing process, handling purified product that is the result of tremendous effort and cost, and there are no second chances at this stage. Once filled, these containers may be frozen for short or long-term storage and will eventually be transported to the drug product facilities for final formulation and filling into vials, syringes or ampules.

 

Bulk filling is performed to solve two inventory management problems associated with any supply chain: risk and better matching supply with demand. Where patients’ lives are concerned and ensuring product is made available when needed most, disruptions to the supply of drug substance are not acceptable. From a risk perspective, dividing the product into smaller lot sizes allows for the risk of disruption owing to, for example, container integrity breach to be minimized. With the correct processes in place, it is not uncommon for drug substance to be stored for up to 10 years at ultra-low temperatures. Once formulated however, shelf-life does become a determining factor and spoilage of high-value therapies negatively impacts the drug manufacturers’ bottom line. Mismatches in demand and supply are inevitable but, with smaller lot sizes, it does become easier for drug product facilities to better minimize quality risks, meet demand and reduce the risk of spoilage. 

 

Next week, in our next blog we review the complexities of bulk filling in part 2.

 

Follow us on social media now to get access to the latest news, updates and events

 

 

Jeremy Rautenbach

Jeremy Rautenbach is an Account Manager within our Australia team. Jeremy has held numerous positions within media operations, product development and strategic marketing with us. Most recently, he was the Global Product Manager for the Integrated Solutions and the single-use bulk filling, tangential flow filtration and chromatography equipment portfolios. Through a combination of customer insight, product development and lifecycle management activities, Jeremy focused on delivering customer-centric process solutions to industrialize bioprocesses in a way that brings life-saving therapies to market faster. He holds an MS in mechanical engineering from the MIT School of Engineering and an MBA from the MIT Sloan School of Management. When not at work, Jeremy enjoys offshore fishing, sailing, and hiking with his family.
Jeremy Rautenbach is an Account Manager within our Australia team. Jeremy has held numerous positions within media operations, product development and strategic marketing with us. Most recently, he was the Global Product Manager for the Integrated Solutions and the single-use bulk filling, tangential flow filtration and chromatography equipment portfolios. Through a combination of customer insight, product development and lifecycle management activities, Jeremy focused on delivering customer-centric process solutions to industrialize bioprocesses in a way that brings life-saving therapies to market faster. He holds an MS in mechanical engineering from the MIT School of Engineering and an MBA from the MIT Sloan School of Management. When not at work, Jeremy enjoys offshore fishing, sailing, and hiking with his family.
더 읽어보기

 

 

  • Category
  • Author
  • Sort By
Results